Mount Sinai receives $500,000 SU2C grant to explore therapies for lung cancer patients with KRAS mutations

FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC

FDA has approved Ibtrozi (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.

June 13, 2025

Vol.51 No.23

Clinical

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

For more than a year before her stage 4 lung cancer was found, 35-year-old Alisa Secaida, a never-smoker and a physically active Southern Californian, had been experiencing a persistent cough and, increasingly, fatigue.

June 06, 2025

Vol.51 No.22

By Claire Marie Porter

Clinical Roundup

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments.

June 06, 2025

Vol.51 No.22

Clinical Roundup

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer improved long-term survival overall compared with chemotherapy alone, according to a clinical trial published June 2 in The New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology.

June 06, 2025

Vol.51 No.22

Clinical Roundup

Poorly functioning blood vessels lead to muscle wasting in cancer, preclinical study finds

A dysfunction in muscle blood vessels could be to blame for the weak muscles and weight loss that most cancer patients experience, according to a new study from University of Illinois Chicago researchers.

June 06, 2025

Vol.51 No.22

Clinical Roundup

OncoHost study offers insights into resistance mechanisms in immunotherapy-treated lung cancer

A recent OncoHost study provides insight in understanding resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer. Through a comprehensive bioinformatic analysis of pretreatment plasma proteomic profiles from 272 NSCLC patients, researchers identified key biological processes associated with resistance and revealed therapeutic targets that could inform future precision treatment strategies.

June 06, 2025

Vol.51 No.22

Mount Sinai receives $500,000 SU2C grant to explore therapies for lung cancer patients with KRAS mutations

YOU MAY BE INTERESTED IN

FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Poorly functioning blood vessels lead to muscle wasting in cancer, preclinical study finds

OncoHost study offers insights into resistance mechanisms in immunotherapy-treated lung cancer

Renew today!

Subscriber content

Never miss an issue!

Login

Mount Sinai receives $500,000 SU2C grant to explore therapies for lung cancer patients with KRAS mutations

YOU MAY BE INTERESTED IN

FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC

Young women are now diagnosed with cancer at twice the rate of young menThe face of cancer is changing at a time when research is plagued by existential threats

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Poorly functioning blood vessels lead to muscle wasting in cancer, preclinical study finds

OncoHost study offers insights into resistance mechanisms in immunotherapy-treated lung cancer

Never miss an issue!

Login

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats